05-535
Anti-IKKβ Antibody, clone 10AG2
clone 10AG2, Upstate®, from mouse
동의어(들):
I-kappa-B kinase 2, I-kappa-B-kinase beta, Nuclear factor NF-kappa-B inhibitor kinase beta, inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta, inhibitor of nuclear factor kappa B kinase beta subunit
로그인조직 및 계약 가격 보기
모든 사진(2)
About This Item
UNSPSC 코드:
12352203
eCl@ss:
32160702
NACRES:
NA.41
추천 제품
생물학적 소스
mouse
Quality Level
항체 형태
purified immunoglobulin
항체 생산 유형
primary antibodies
클론
10AG2, monoclonal
종 반응성
rat, human, mouse
제조업체/상표
Upstate®
기술
western blot: suitable
동형
IgG1
NCBI 수납 번호
UniProt 수납 번호
배송 상태
dry ice
타겟 번역 후 변형
unmodified
유전자 정보
mouse ... Ikbkb(16150)
일반 설명
IKK beta (I-Kappa-B kinase-beta) is a member of the IKK complex which is composed of IKK alpha, IKK beta, IKK gamma and IKAP. Phosphorylation of I-Kappa-B on a serine residue by the IKK complex frees NF-kB from I-Kappa-B and marks it for degradation via ubiquination. IKK beta has been shown to activate NF-kB and phosphorylate IKB alpha and beta. Phosphorylation of 2 sites at the activation loop of IKK beta is essential for activation of IKK by TNF and IL1. Once activated, IKK beta autophosphorylates which in turn decreases IKK activity and prevents prolonged activation of the inflammatory response. Additionally, IKK beta activity can also be regulated by MEKK-1.
특이성
Other species not tested.
This antibody recognizes IKKβ/IKK2, Mr 87 kDa.
면역원
His-tagged, full length human IKKβ/IKK2. Clone: 10AG2.
애플리케이션
Anti-IKKβ Antibody, clone 10AG2 detects level of IKKβ & has been published & validated for use in WB.
품질
Routinely evaluated by western blot on human Jurkat RIPA cell lysate, human A431, HeLa nuclear extract, mouse 3T3/A31 or rat PC-12 RIPA cell lysates.
Western Blot Analysis:
0.5-2 µg/mL of this lot detected IKK/IKK2 in human HeLa cell lysate. A previous lot was tested in human Jurkat RIPA cell lysate, A431, extract, mouse 3T3/A31 and rat PC-12 RIPA cell lysates.
Western Blot Analysis:
0.5-2 µg/mL of this lot detected IKK/IKK2 in human HeLa cell lysate. A previous lot was tested in human Jurkat RIPA cell lysate, A431, extract, mouse 3T3/A31 and rat PC-12 RIPA cell lysates.
표적 설명
87 kDa
물리적 형태
Format: Purified
Purified mouse monoclonal IgG1 in buffer containing PBS and 0.05% sodium azide. Frozen solution.
분석 메모
Control
Positive Antigen Control: Catalog #12-303, Jurkat cell lysate.
Positive Antigen Control: Catalog #12-303, Jurkat cell lysate.
기타 정보
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
법적 정보
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
적합한 제품을 찾을 수 없으신가요?
당사의 제품 선택기 도구.을(를) 시도해 보세요.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Emmanuel Derudder et al.
Proceedings of the National Academy of Sciences of the United States of America, 113(18), 5065-5070 (2016-04-22)
Although canonical NF-κB signaling is crucial to generate a normal mature B-cell compartment, its role in the persistence of resting mature B cells is controversial. To resolve this conflict, we ablated NF-κB essential modulator (NEMO) and IκB kinase 2 (IKK2)
Siddharth Bakshi et al.
The Biochemical journal, 474(7), 1163-1174 (2017-02-06)
The double-stranded RNA mimetic poly(I:C) and lipopolysaccharide (LPS) activate Toll-like receptors 3 (TLR3) and TLR4, respectively, triggering the activation of TANK (TRAF family member-associated NF-κB activator)-binding kinase 1 (TBK1) complexes, the phosphorylation of interferon regulatory factor 3 (IRF3) and transcription
Crystal structure of inhibitor of ?B kinase ?.
Xu, G; Lo, YC; Li, Q; Napolitano, G; Wu, X; Jiang, X; Dreano, M; Karin, M; Wu, H
Nature null
Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells.
Matthew C Catley, Joanna E Chivers, Neil S Holden, Peter J Barnes, Robert Newton
British Journal of Pharmacology null
Daniela S Bassères et al.
Genes & cancer, 5(1-2), 41-55 (2014-06-24)
Activating mutations in KRAS are prevalent in cancer, but therapies targeted to oncogenic RAS have been ineffective to date. These results argue that targeting downstream effectors of RAS will be an alternative route for blocking RAS-driven oncogenic pathways. We and
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.